Paper Details

  1. Home
  2. Paper Details

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.

Author: ChariAjai, EtheredgeDelores, FlemingSarah, JagannathSundar, KrishnanAmrita Y, LinThomas S, LiuBaolian, LondheAnil, LonialSagar, MarkTomer M, NookaAjay K, Stockerl-GoldsteinKeith E, UkropecJon, UsmaniSaad Z

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Daratumumab was well-tolerated and showed a consistent safety profile in heavily pretreated patients with relapsed or refractory multiple myeloma (MM). The most common adverse events were thrombocytopenia, anemia, and infusion reactions. Montelukast premedication may help to reduce the rate of infusion reactions.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Daratumumab is a human CD38-directed monoclonal antibody indicated for the treatment of relapsed and refractory multiple myeloma (MM). METHODS: A multicenter, open-label treatment protocol provided early access to daratumumab for patients who had progressive MM after they received ≥3 pr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6587745/

データ提供：米国国立医学図書館（NLM）

Daratumumab: A New Hope for Relapsed or Refractory Multiple Myeloma

The treatment of relapsed or refractory multiple myeloma (MM) continues to be a challenge for oncologists. This study explores the use of daratumumab, a human CD38-directed monoclonal antibody, in patients with MM who have progressed after receiving multiple prior lines of therapy. The study evaluated the safety and efficacy of daratumumab in this challenging patient population. The findings suggest that daratumumab is well-tolerated and shows promising activity in patients with relapsed or refractory MM. The study highlights the potential of daratumumab as a valuable therapeutic option for patients with limited treatment options.

Fighting Myeloma: A New Weapon in the Arsenal

The study's findings offer a glimmer of hope for patients with relapsed or refractory MM, a disease known for its difficult-to-treat nature. Daratumumab's effectiveness and safety in this patient population demonstrate its potential as a valuable weapon in the fight against MM. The drug's ability to target CD38, a protein found on myeloma cells, allows it to selectively kill cancer cells while minimizing harm to healthy cells.

Navigating the Complexities of Cancer Treatment

Treating cancer is like navigating a complex desert with shifting sands and unpredictable storms. This study offers valuable insights into the use of daratumumab for relapsed or refractory MM. While daratumumab shows promise, it's important to remember that every patient is unique, and treatment decisions must be made on a case-by-case basis. With careful monitoring and individualized therapy, daratumumab can provide a beacon of hope for patients facing this challenging disease.

Dr.Camel's Conclusion

Daratumumab demonstrates promising potential as a treatment for relapsed or refractory MM, offering new hope for patients with limited treatment options. The drug's safety and efficacy in this challenging patient population highlight its potential as a valuable addition to the existing therapeutic arsenal. As we continue to navigate the complexities of cancer treatment, daratumumab provides a glimmer of hope for patients facing this challenging disease.

Date :
  1. Date Completed 2019-09-11
  2. Date Revised 2021-12-04
Further Info :

Pubmed ID

30395359

DOI: Digital Object Identifier

PMC6587745

Related Literature

Article Analysis
・Effects of daratumumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.